Articles tagged with: Orphan medicinal products
Rethinking the Orphan Regulation Partner Content
19 May
Rethinking the Orphan Regulation
Europe risks undercutting its best asset for treating millions of rare cancer sufferers, says Stéphane Lassignardie, VP for Region North & Oncology at AbbVie Europe.
Orphan Regulation: Time for a rethink? Partner Content
19 May
Orphan Regulation: Time for a rethink?
The upcoming review is an opportunity to not only accelerate the development of rare disease treatments, but also to provide equitable access for patients across Europe, says MEP Nicolás González Casares, S&D group shadow rapporteur on the EU’s Beating Cancer Plan report.
Orphan medicinal products: onwards and upwards
28 Feb
Orphan medicinal products: onwards and upwards
The Orphan Medicinal Products regulation delivered impressive results for rare disease patients, but the pending revision can move it up a gear, argues Stelios Kympouropoulos
Rare Diseases: Securing a better future for rare disease patients across Europe is a shared responsibility
23 Feb
Rare Diseases: Securing a better future for rare disease patients across Europe is a shared responsibility
Meeting unmet needs together is essential, explains Takeda Pharmaceuticals Chief Giles Platford.